Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UPDATED: Regeneron Wins Same-Day Veopoz, High-Dose Eylea US FDA Approvals

Products Produced At Same Catalent Site

Executive Summary

Veopoz (pozelimab) approval showed the FDA was reassured that Regeneron’s contract manufacturer is ready to supply high-dose Eylea, a key product for the company as competition picks up.

You may also be interested in...

Regeneron Sees Further Growth For Eylea HD As Reimbursement Path Gets Smoother

The drug maker reported $123m in sales for the higher-dose version of Eylea in the first full quarter of sales since its approval last August.

Bayer’s Pipeline Refresh Focuses On Early Stage Despite Near-Term Growth Needs

The company is struggling to grow revenue, and the biggest of its four key late-stage assets had a setback, but novel technologies are fueling an R&D strategy shift towards high potential programs.

Regeneron Expands Bispecifics, Gene Therapy Programs As Exec Hints At More Deals

The drug maker reported what it said were encouraging early uptake signs for Eylea HD while also seeking to reassure analysts concerned about its BCMA-directed bispecific’s differentiation.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts